ThinkCyte Secures $26 million in Series B Financing
ThinkCyte Secures $26 million in Series B Financing Funding will be used to advance the development of AI-based cell analysis and sorting platforms in cell therapy and diagnostics. News provided by Share this article Share this article TOKYO, May 19, 2021 /PRNewswire/ -- ThinkCyte, Inc., a company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, announced today the completion of a $26 million (JPY 2.85 billion) Series B financing, led by SPARX Group with participation from Sysmex Corporation and Sumitomo Mitsui Trust Investment as well as existing ...
Source: prnewswire.com